NanoViricides
NNVC
21 hedge funds and large institutions have $365K invested in NanoViricides in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 0 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
48% more capital invested
Capital invested by funds: $247K → $365K (+$118K)
24% more funds holding
Funds holding: 17 → 21 (+4)
0.67% more ownership
Funds ownership: 3.13% → 3.8% (+0.67%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$67.5K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$11.3K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3.56K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.03K |
| 5 |
QCG
Quadrant Capital Group
Cincinnati,
Ohio
|
+$707 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$21.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.46K |
| 3 |
JP Morgan Chase
New York
|
-$2 |
NNVC Hedge Fund Activity: Q4 2019 in Review
21 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in NanoViricides (NNVC) for Q4 2019, worth a combined $365K — up 48% from $247K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NNVC positions and 0 closed out — a net gain of 5 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $67.5K. The largest seller was Vanguard Group, cutting an estimated $21.8K.
- 21 institutional investors held NanoViricides (NNVC) as of Q4 2019, up from 17 in Q3 2019.
- Funds reported $365K of NanoViricides stock for Q4 2019, up 48% quarter-over-quarter.
- 5 funds opened new NanoViricides positions in Q4 2019 and 0 closed out, a net change of +5 holders.
- The largest NanoViricides buyer in Q4 2019 was Renaissance Technologies, an estimated $67.5K added.
- The largest NanoViricides seller in Q4 2019 was Vanguard Group, an estimated $21.8K sold.
Based on aggregated 13F filings for Q4 2019.